EUVIMEDEUVIMED entdecken
Crossref

How Would You Manage HIV Pre-exposure Prophylaxis in This Patient With Medical Comorbidities?

Howard Libman, Douglas Krakower iD, Jessica L Taylor iD, Risa B Burns

Annals of Internal Medicine · 2024

DOI: 10.7326/m24-0217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Internal Medicine, 2024. Verfasst von Howard Libman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Boston, Massachusetts (H.L., D.K., R.B.B.). Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Teaching Rounds, Acquired Immunodeficiency Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in treatment, HIV infection remains an important cause of morbidity and mortality, with more than 30 000 new cases diagnosed in the United States each year. There are several interventions traditionally used to prevent HIV transmission, but these vary in effectiveness and there are challenges to their implementation. In 2014, the Centers for Disease Control and Prevention published initial guidance on the use of antiretroviral pre-exposure prophylaxis (PrEP) to prevent transmission of HIV infection in persons at risk based on multiple studies that showed it to be highly efficacious in various populations. It was updated in 2021 to reflect new drug options. The U.S. Preventive Services Task Force also recently updated its recommendations for PrEP, which strongly support its use in persons at risk. Despite its well-established effectiveness, the implementation of PrEP in clinical practice has been variable, especially among populations underserved by the medical system and marginalized by society. Fewer than one third of persons in the United States who are eligible for PrEP currently receive it. Here, 2 physicians experienced in HIV PrEP debate how best to identify patients who might benefit from PrEP, how to decide what regimen to use, and how to monitor therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPre-Exposure ProphylaxisTeaching RoundsAcquired Immunodeficiency SyndromeAnti-HIV AgentsHumansUnited StatesAnti-Retroviral Agents

Substanzen

Anti-Retroviral AgentsAnti-HIV Agents

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts (H.L., D.K., R.B.B.).
  • Boston University School of Medicine, Section of General Internal Medicine, Boston, Massachusetts (J.L.T.).

ORCID-Profile: Douglas Krakower, Jessica L Taylor

Zitieren

APA

Libman, H., Krakower, D., Taylor, J. L., & Burns, R. B. (2024). How Would You Manage HIV Pre-exposure Prophylaxis in This Patient With Medical Comorbidities?. Annals of Internal Medicine. https://doi.org/10.7326/m24-0217

Vancouver

Libman H, Krakower D, Taylor JL, Burns RB. How Would You Manage HIV Pre-exposure Prophylaxis in This Patient With Medical Comorbidities?. Annals of Internal Medicine. 2024. doi:10.7326/m24-0217

BibTeX
@article{Libman2024,
  author = {Libman, Howard and Krakower, Douglas and Taylor, Jessica L and Burns, Risa B},
  title = {How Would You Manage HIV Pre-exposure Prophylaxis in This Patient With Medical Comorbidities?},
  journal = {Annals of Internal Medicine},
  year = {2024},
  doi = {10.7326/m24-0217}
}
Kostenlos starten →